Insurance coverage for weight loss medications varies widely depending on your plan type, employer, and state, but six FDA-approved drugs are commonly considered for coverage: orlistat (Xenical), phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound). Whether your plan actually pays for any of them depends on several factors, including your BMI, your health conditions, and the type of insurance you carry.
FDA-Approved Options for Long-Term Use
The FDA has approved six medications for long-term weight management in adults. They work through different mechanisms, which matters because if one isn’t covered by your plan, another might be.
- Orlistat (Xenical): Blocks fat absorption in the gut. Also available over the counter at a lower dose as Alli.
- Phentermine-topiramate (Qsymia): Combines an appetite suppressant with an anti-seizure medication that also reduces hunger.
- Naltrexone-bupropion (Contrave): Pairs an addiction-treatment drug with an antidepressant to target appetite-regulating pathways in the brain.
- Liraglutide (Saxenda): A daily injection that mimics a gut hormone called GLP-1 to reduce appetite.
- Semaglutide (Wegovy): A weekly GLP-1 injection, similar to Saxenda but typically producing greater weight loss.
- Tirzepatide (Zepbound): A weekly injection that mimics two gut hormones (GLP-1 and GIP) to suppress appetite and regulate blood sugar.
A seventh medication, setmelanotide (Imcivree), is only approved for people with specific rare genetic obesity disorders confirmed by genetic testing. It occupies a separate coverage category entirely.
Commercial Insurance: Coverage Is Growing but Still Limited
If you get insurance through an employer, your chances of having GLP-1 medications like Wegovy or Zepbound covered depend heavily on the size of the company. As of 2025, only 19% of firms with more than 200 workers cover GLP-1 drugs for weight loss in their largest health plan. That number jumps to 43% among companies with 5,000 or more employees, up from 28% in 2024. Smaller employers (200 to 999 workers) sit at just 16%.
Even when a plan does cover these medications, you’ll almost certainly face prior authorization requirements before the pharmacy can fill the prescription. Older, less expensive options like orlistat, Qsymia, and Contrave are more commonly included on formularies, though they also frequently require prior authorization. Some plans place GLP-1 drugs on the highest copay tier, which can mean monthly out-of-pocket costs of $200 to $500 even with coverage.
What Insurers Require for Approval
Prior authorization for weight loss drugs follows a fairly standard pattern across most commercial and government plans. You typically need to meet one of two BMI thresholds:
- BMI of 30 or higher with no additional conditions required.
- BMI of 27 to 29.9 plus two or more weight-related health conditions. Qualifying conditions usually include high cholesterol, high blood pressure, sleep apnea, type 2 diabetes, or established cardiovascular disease (history of heart attack, stroke, or related procedures).
Your doctor submits documentation of your BMI and any qualifying conditions. Some plans also require evidence that you’ve tried lifestyle modifications like diet and exercise programs before they’ll approve medication. The turnaround for prior authorization decisions is typically a few days to two weeks.
Staying on the Medication: Renewal Criteria
Getting approved once doesn’t guarantee ongoing coverage. Most plans reassess after an initial approval period, commonly six months. To continue receiving the medication, you generally need to show at least 5% loss of your starting body weight. For adolescents aged 12 to 17, the threshold is typically a 5% reduction in baseline BMI. If you don’t meet that benchmark, your insurer may deny renewal, though your doctor can submit an appeal explaining why continued treatment is still appropriate.
Medicare: A Complicated Picture
Medicare Part D has historically excluded drugs prescribed solely for weight loss. However, two important exceptions have opened the door. Wegovy received FDA approval to reduce the risk of major cardiovascular events in adults with established heart disease and obesity or overweight. Zepbound was approved for moderate to severe obstructive sleep apnea in adults with obesity. When prescribed for these specific conditions rather than weight loss alone, these drugs can be covered through standard Part D formulary processes.
For Medicare beneficiaries who need GLP-1 drugs primarily for weight management, CMS has announced a short-term demonstration program called the Medicare GLP-1 Bridge, set to run from July 2026 through December 2027. This program will operate outside the normal Part D benefit structure and is designed to provide temporary access while longer-term coverage policies are developed. Beneficiaries who already qualify for coverage under one of the approved non-obesity indications (cardiovascular risk reduction or sleep apnea) would continue through their Part D plan rather than the bridge program.
Medicaid: Only 13 States Cover GLP-1s for Obesity
Medicaid coverage for weight loss medications is the most restrictive. As of January 2026, only 13 state Medicaid programs cover GLP-1 drugs for obesity treatment under fee-for-service. The landscape has been unstable: four states (California, New Hampshire, Pennsylvania, and South Carolina) eliminated GLP-1 obesity coverage after previously offering it. North Carolina dropped coverage in October 2025 due to a budget dispute but reinstated it two months later.
Even in states that do cover these medications through Medicaid, prior authorization requirements and utilization controls can create significant barriers. Older weight loss drugs like orlistat and Contrave are more widely available on state Medicaid formularies, though coverage still varies state by state.
What to Do If You’re Denied
A denial isn’t necessarily the final answer. The first step is requesting a written explanation with the specific reason for the denial. Common denial categories include “not medically necessary,” “experimental,” or “excluded benefit,” and each requires a different response.
If the denial says the medication isn’t medically necessary, verify that the correct billing and diagnosis codes were submitted. Then ask your doctor to write a letter documenting your BMI, all weight-related health conditions (diabetes, heart disease, sleep apnea, high blood pressure), and why the medication is clinically appropriate for you. If the denial categorizes the drug as experimental, your doctor’s letter should emphasize the FDA approval status and clinical evidence supporting its use.
For denials based on the medication being an excluded benefit, meaning your plan simply doesn’t cover weight loss drugs, the appeal process is harder but not impossible. Make sure every relevant comorbidity is documented and coded correctly, as coverage may exist when the primary diagnosis is a covered condition like cardiovascular disease rather than obesity alone. If you’re on an employer self-insured plan, you’ll need a formal written denial (an Explanation of Benefits) before you can file an appeal.
Throughout this process, keep records of every communication and submission. Many denials are overturned on appeal, particularly when the initial submission was missing documentation or used incorrect codes.
Manufacturer Savings Programs
Both Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) offer savings programs, but their usefulness depends on your insurance situation. Manufacturer copay cards are generally designed for people with commercial insurance and can reduce monthly costs significantly. However, if your plan explicitly excludes the medication, the savings card may not apply, and some programs require you to select “self-pay” rather than running the card through insurance. People on Medicare or Medicaid are typically ineligible for manufacturer copay assistance due to federal regulations. The terms change frequently, so checking directly with the manufacturer’s website gives you the most current information for your specific situation.